Table 4. Association between the expression level of RAB11B and the clinic characteristics of the patients.
| Clinic characteristics | Southern samples, N (%) | Pa | Eastern samples, N (%) | Pa | Merged samples, N (%) | Pa | |||
|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | ||||
| Age | |||||||||
| <60 | 46 (43.8) | 59 (56.2) | 0.762 | 22 (43.1) | 29 (56.9) | 0.919 | 68 (43.6) | 88 (56.4) | 0.856 |
| ≥60 | 32 (41.6) | 45 (58.4) | 19 (44.2) | 24 (55.8) | 51 (42.5) | 69 (57.5) | |||
| Sex | |||||||||
| Female | 24 (46.2) | 28 (53.8) | 0.570 | 12 (42.9) | 16 (57.1) | 0.923 | 36 (45.0) | 44 (55.0) | 0.686 |
| Male | 54 (41.5) | 76 (58.5) | 29 (43.9) | 37 (56.1) | 83 (42.3) | 113 (57.7) | |||
| Family history of cancer | |||||||||
| No | 67 (41.6) | 94 (58.4) | 0.348 | 37 (44.0) | 47 (56.0) | 0.807 | 104 (42.4) | 141 (57.6) | 0.529 |
| Yes | 11 (52.4) | 10 (47.6) | 4 (40.0) | 6 (60.0) | 15 (45.2) | 16 (54.8) | |||
| Family history of lung cancer | |||||||||
| No | 73 (43.2) | 96 (56.8) | 0.740 | 40 (44.0) | 51 (56.0) | 0.715 | 113 (43.5) | 147 (56.5) | 0.640 |
| Yes | 5 (38.5) | 8 (61.5) | 1 (33.3) | 2 (66.7) | 6 (37.5) | 10 (62.5) | |||
| Smoking | |||||||||
| No | 31 (46.3) | 36 (53.7) | 0.478 | 14 (46.7) | 16 (53.3) | 0.683 | 45 (46.4) | 52 (53.6) | 0.419 |
| Yes | 47 (40.9) | 68 (59.1) | 27 (42.2) | 37 (57.8) | 74 (41.9) | 105 (58.1) | |||
| Drinking | |||||||||
| No | 60 (43.8) | 77 (56.2) | 0.655 | 31 (42.5) | 42 (57.5) | 0.675 | 91 (43.3) | 119 (56.7) | 0.897 |
| Yes | 18 (40.0) | 27 (60.0) | 10 (47.6) | 11 (52.4) | 28 (42.4) | 38 (57.6) | |||
| Surgery | |||||||||
| No | 54 (44.6) | 67 (55.4) | 0.497 | 25 (43.1) | 33 (56.9) | 0.899 | 79 (44.1) | 100 (55.9) | 0.643 |
| Yes | 24 (39.3) | 37 (60.7) | 16 (44.4) | 20 (55.6) | 40 (41.2) | 57 (58.8) | |||
| Chemotherapy | |||||||||
| No | 24 (38.1) | 39 (61.9) | 0.345 | 12 (41.4) | 17 (58.6) | 0.770 | 36 (39.1) | 56 (60.9) | 0.344 |
| Yes | 54 (45.4) | 65 (54.6) | 29 (44.6) | 36 (55.4) | 83 (45.1) | 101 (54.9) | |||
| Radiotherapy | |||||||||
| No | 47 (45.2) | 57 (54.8) | 0.462 | 22 (45.8) | 26 (54.2) | 0.658 | 69 (45.4) | 83 (54.6) | 0.397 |
| Yes | 31 (39.7) | 47 (60.3) | 19 (41.3) | 27 (58.7) | 50 (40.3) | 74 (59.7) | |||
| Clinical stages | |||||||||
| I + II | 40 (56.3) | 31 (43.7) | 0.003 | 18 (62.1) | 11 (37.9) | 0.016 | 58 (58.0) | 42 (42.0) | <0.001 |
| III + IV | 38 (34.2) | 73 (65.8) | 23 (35.4) | 42 (64.6) | 61 (34.7) | 115 (65.3) | |||
| T | |||||||||
| 1+2 | 50 (48.1) | 54 (51.9) | 0.100 | 19 (42.2) | 26 (57.8) | 0.794 | 69 (46.3) | 80 (53.7) | 0.246 |
| 3+4 | 28 (35.9) | 50 (64.1) | 22 (44.9) | 27 (55.1) | 50 (39.4) | 77 (60.6) | |||
| N | |||||||||
| 0 | 35 (53.0) | 31 (37.0) | 0.036 | 26 (60.5) | 17 (39.5) | 0.002 | 61 (56.0) | 48 (44.0) | <0.001 |
| 1+2+3 | 43 (37.1) | 73 (62.9) | 15 (29.4) | 36 (70.6) | 58 (34.7) | 109 (65.3) | |||
| M | |||||||||
| 0 | 63 (48.8) | 66 (51.2) | 0.011 | 32 (53.3) | 28 (46.7) | 0.012 | 95 (50.3) | 94 (49.7) | <0.001 |
| 1 | 15 (28.3) | 38 (71.7) | 9 (26.5) | 25 (73.5) | 24 (27.6) | 63 (72.4) | |||
| Histological types | |||||||||
| Adenocarcinoma | 39 (45.3) | 47 (54.7) | 0.693 | 20 (48.8) | 21 (51.2) | 0.600 | 59 (46.5) | 68 (53.4) | 0.612 |
| Squamous cell carcinoma | 20 (39.2) | 31 (60.8) | 10 (32.3) | 21 (67.7) | 30 (36.6) | 52 (63.4) | |||
| Large cell carcinoma | 4 (66.7) | 2 (33.3) | 2 (40.0) | 3 (60.0) | 6 (54.5) | 5 (45.5) | |||
| Small cell lung cancer | 7 (36.8) | 12 (63.2) | 4 (50.0) | 4 (50.0) | 11 (40.7) | 16 (59.3) | |||
| Other carcinomasb | 8 (40.0) | 12 (60.0) | 5 (55.6) | 4 (44.4) | 13 (44.8) | 16 (55.2) | |||
a, Pearson χ2 test P value; b, mixed-cell or undifferentiated carcinoma.